<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00618410</url>
  </required_header>
  <id_info>
    <org_study_id>15835A</org_study_id>
    <nct_id>NCT00618410</nct_id>
  </id_info>
  <brief_title>Intranasal CO2 for Allergic Rhinitis</brief_title>
  <official_title>Intranasal CO2 for Allergic Rhinitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Chicago</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Capnia, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Chicago</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to better understand the way in which CO2 (carbon dioxide)
      affects the symptoms of allergic rhinitis or hayfever.

      Our intent is to determine if CO2 has an effect on nasal challenge with antigen as a
      predictor of whether it will have a beneficial effect on the treatment of seasonal allergic
      rhinitis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design: We performed a randomized, two-way crossover study in subjects with seasonal
      allergic rhinitis out of season. Subjects came to the Nasal Physiology Laboratory for
      screening, where they completed an allergy questionnaire and underwent skin-prick testing for
      confirmation of a grass or ragweed allergy. The skin test included positive and negative
      controls and the results were graded compared with the controls as 1+ to 4+ (1+: wheal larger
      than negative control and smaller than positive control; 2+: wheal 5-7 mm; 3+: wheal 7-10 mm;
      4+: any reaction with a wheal &gt;10 mm or pronounced pseudopodia). Subjects with positive skin
      test (between 2+ and 4+) and a positive history of allergic symptoms during the relevant
      seasons then underwent a screening nasal challenge with either grass or ragweed allergen.
      Subjects who passed the screening challenge (twofold increase in either ipsilateral or
      contralateral nasal secretions after allergen challenge compared with diluent) had a 2-week
      washout period and returned to the laboratory, where they were randomized to receive
      intranasal treatment with either CO2 or no treatment. Thirty minutes after treatment,
      subjects underwent a nasal challenge with allergen. Seven subjects were challenged with
      ragweed and five subjects were challenged with grass. Subjects had another 2-weeks washout
      period and were then crossed over to the other treatment followed by a similar challenge.
      Previous work in our laboratory using a similar challenge system showed that allergen-induced
      inflammatory changes are back to baseline 2 weeks after the challenge.

      Subjects: Twelve subjects participated. Subjects were studied outside their allergy season.
      All subjects were healthy except for mild asthma requiring only as-needed bronchodilators.
      They were not on any medications and had not received antihistamines or leukotriene receptor
      antagonists for at least 1 week and intranasal steroids for at least 1 month before
      enrollment and for the duration of the study.

      Treatment: CO2 was applied for 10 seconds in each nostril using a special applicator (plastic
      tight-seal nosepiece) attached to a CO2 canister and a flow control valve. It was delivered
      at a flow rate of 0.5 standard L/min with the mouth open to prevent inhalation. Thus, for
      20-second duration of administration, the total dose of CO2 delivered was 167 mL. The amount
      of CO2 delivered to the mucosa is unknown. The no-treatment arm involved placement of the
      device but no gas was delivered. Therefore, neither the subjects nor the investigators were
      blinded to the treatment administered. The no-treatment arm did not involve the delivery of
      air without CO2 to the nose because we were concerned that blowing dry air into the nose
      might cause a mucosal reaction that could confound the results. We have previously shown that
      cold, dry air challenges create a hyperosmolar environment, triggers mast cell activation,
      and induces a nasonasal reaction.7 Thus, because our primary outcome was the objective
      measure of the nasonasal reflex, we avoided this possibility.

      Nasal Challenge: The subjects were allowed 15 minutes to acclimatize to the laboratory
      environment before challenge. Baseline sneezes reflecting the 15 minutes of acclimatization
      and nasal and eye symptoms were recorded followed by collection of a nasal scraping for
      quantitation of eosinophils in nasal secretions. Sneezes were recorded by the subjects during
      each of the assessed intervals of the challenge protocol. The subjects were reminded to keep
      track of the number of sneezes by the research coordinator who was present for the duration
      of the challenges. Intranasal CO2 or sham was then applied for 10 seconds to each nostril.
      Thirty minutes later, sneezes and symptoms were recorded again, to reflect the 30-minute time
      period, and nasal challenge was initiated. Because we were interested in evaluating the
      effect of the treatment on allergen-induced nasal reflexes, we used filter paper disks to
      perform the challenges and monitor the secretory response as previously described.

      Briefly, 8-mm filter paper disks (Shandon, Inc., Pittsburgh, PA) were used for both nasal
      challenge and collection of resultant secretions. They were placed on the anterior nasal
      septum, beyond the mucocutaneous junction, under direct vision using a nasal speculum,
      forceps, and a headlight. Fifty microliters of challenge solutions were placed on the disks,
      which were then applied to the nasal septum for 1 minute. Thirty seconds after removal, two
      preweighed filter paper disks were placed on both sides of the nasal septum for 30 seconds,
      collecting nasal secretions from the challenge site (ipsilateral) and the contralateral
      nostril. These disks were then immediately placed back into microtubes and weighed. The
      difference in their weight before and after challenge was the weight of produced nasal
      secretions, which was recorded in milligrams. Ten minutes after each challenge, the number of
      sneezes as well as symptoms on each side were recorded by the subjects reflective of the
      10-minute interval The first challenge was performed using phenol-buffered saline, the
      diluent for the allergen extracts, and this was followed by 2 increasing doses of grass or
      ragweed allergen. The time from treatment administration to the first allergen challenge was
      approximately 40 minutes and to the second allergen challenge, 50 minutes. The amount of
      allergen applied on the paper disks for challenge were 333 and 1000 BAU (bioequivalent
      allergy unit) of grass allergen extract (Hollister-Stier, Spokane, WA) or 50 microliters of
      ragweed antigen extract at concentrations of 1:666 and 1:200 w/v (Hollister-Stier). The
      subjects came back to the laboratory 24 hours later and underwent a scraping of their nasal
      secretions to evaluate for eosinophil influx.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Diluent Challenge Contralateral Secretion Weight at Antigen Challenge</measure>
    <time_frame>10 minutes post diluent challenge and 10 minutes post antigen challenge</time_frame>
    <description>Fifty microliters of challenge solutions were placed on the disks, which were then applied to the nasal septum for 1 minute. Thirty seconds after removal, two preweighed filter paper disks were placed on both sides of the nasal septum for 30 seconds, collecting nasal secretions from the challenge site (ipsilateral) and the contralateral nostril. These disks were then immediately placed back into microtubes and weighed. The difference in their weight before and after challenge was the weight of produced nasal secretions, which was recorded in milligrams. Contralateral secretion weight for the diluent challenge was subtracted from that of the antigen challenge to compute this primary outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Diluent Challenge Ipsilateral Secretion Weight at Antigen Challenge</measure>
    <time_frame>10 minutes post diluent challenge and 10 minutes post antigen challenge</time_frame>
    <description>Fifty microliters of challenge solutions were placed on the disks, which were then applied to the nasal septum for 1 minute. Thirty seconds after removal, two preweighed filter paper disks were placed on both sides of the nasal septum for 30 seconds, collecting nasal secretions from the challenge site (ipsilateral) and the contralateral nostril. These disks were then immediately placed back into microtubes and weighed. The difference in their weight before and after challenge was the weight of produced nasal secretions, which was recorded in milligrams. Ipsilateral secretion weight for the diluent challenge was subtracted from that of the antigen challenge to compute this primary outcome measure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Diluent Challenge Ipsilateral Histamine Level at Antigen Challenge</measure>
    <time_frame>10 minutes post diluent challenge and 10 minutes post antigen challenge</time_frame>
    <description>After collection of nasal secretions after diluent or antigen challenge, the filter paper disks were replaced in Eppendorf tubes and the disk/tube combination was weighed to record produced secretions. Three hundred microleters of 0.9% sodium chloride solution was then placed in the tubes and mediators were allowed to elute from the disks for 24 hours at 4 degrees Celsius. The eluate was then transferred to tubes and stored at -20 degrees Celsius until assayed for histamine.
Histamine was assayed by ELISA (Oxford Biomedical Research, Oxford, MI). The lower limit of detection of the assay is 2.5 ng/mL and samples below the detection limit were arbitrarily assigned a value of 1.25 ng/mL. The ipsilateral measure was taken from the challenge site.
The number reported in this outcome measure was calculated by subtracting the ipsalateral histamine level at diluent challenge from the analogous measure recorded after antigen challenge. Values may be positive or negative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Diluent Challenge Contralateral Histamine Level at Antigen Challenge</measure>
    <time_frame>10 minutes post diluent challenge and 10 minutes post antigen challenge</time_frame>
    <description>After collection of nasal secretions after diluent or antigen challenge, the filter paper disks were replaced in Eppendorf tubes and the disk/tube combination was weighed to record produced secretions. Three hundred microleters of 0.9% sodium chloride solution was then placed in the tubes and mediators were allowed to elute from the disks for 24 hours at 4 degrees Celsius. The eluate was then transferred to tubes and stored at -20 degrees Celsius until assayed for histamine.
Histamine was assayed by ELISA (Oxford Biomedical Research, Oxford, MI). The lower limit of detection of the assay is 2.5 ng/mL and samples below the detection limit were arbitrarily assigned a value of 1.25 ng/mL. The ipsilateral measure was taken from the challenge site.
The number reported in this outcome measure was calculated by subtracting the contralateral histamine level at diluent challenge from the analogous measure recorded after antigen challenge. Values may be positive or negative.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophil Influx [Pre-allergen]</measure>
    <time_frame>before antigen challenge</time_frame>
    <description>The number of eosinophils per 200 white blood cells was counted for each nasal secretion scraping. The percentage of eosinophils was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eosinophil Influx [Post-allergen]</measure>
    <time_frame>after antigen challenge</time_frame>
    <description>The number of eosinophils per 200 white blood cells was counted for each nasal secretion scraping. The percentage of eosinophils was recorded.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Allergic Rhinitis</condition>
  <arm_group>
    <arm_group_label>Carbon dioxide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>nasal Carbon dioxide, USP (CO2) administered 30 minutes prior to nasal challenge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>nasal placebo administered 30 minutes prior to nasal challenge</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Carbon dioxide, USP</intervention_name>
    <description>Carbon dioxide (CO2) delivered via a nosepiece at a flow rate of 0.5 (Â± 0.05) SLPM for 10 seconds /nostril</description>
    <arm_group_label>Carbon dioxide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Nasal placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Males and females between 18 and 45 years of age.

          2. History of grass and/or ragweed allergic rhinitis.

          3. Positive skin test to grass and/or ragweed antigen.

          4. Positive response to screening nasal challenge.

        Exclusion Criteria

          1. Physical signs or symptoms suggestive of renal, hepatic or cardiovascular disease.

          2. Pregnant or lactating women.

          3. Upper respiratory infection within 14 days of study start.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Naclerio, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Chicago</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Baroody FM, Gavanescu L, Wang JH, DeTineo M, Naclerio RM. The effect of intranasal carbon dioxide on the acute response to nasal challenge with allergen. Allergy Asthma Proc. 2011 May-Jun;32(3):206-12. doi: 10.2500/aap.2011.32.3442.</citation>
    <PMID>21703101</PMID>
  </results_reference>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2008</study_first_submitted>
  <study_first_submitted_qc>February 19, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 20, 2008</study_first_posted>
  <results_first_submitted>August 28, 2013</results_first_submitted>
  <results_first_submitted_qc>December 9, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 27, 2014</results_first_posted>
  <last_update_submitted>December 9, 2013</last_update_submitted>
  <last_update_submitted_qc>December 9, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 27, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Chicago</investigator_affiliation>
    <investigator_full_name>Robert Naclerio</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Carbon Dioxide, Then Placebo</title>
          <description>Intervention sequence:
Intervention #1: nasal Carbon dioxide, USP (CO2) administered 30 minutes prior to nasal challenge
Intervention #2: nasal placebo administered 30 minutes prior to nasal challenge</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Then Carbon Dioxide</title>
          <description>Intervention sequence:
Intervention #1: nasal placebo administered 30 minutes prior to nasal challenge
Intervention #2: nasal Carbon dioxide, USP (CO2) administered 30 minutes prior to nasal challenge</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Washout Period (2 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Second Intervention</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Entire Study Population</title>
          <description>Study population includes subjects receiving interventions in either order.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30.69" spread="8.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Diluent Challenge Contralateral Secretion Weight at Antigen Challenge</title>
        <description>Fifty microliters of challenge solutions were placed on the disks, which were then applied to the nasal septum for 1 minute. Thirty seconds after removal, two preweighed filter paper disks were placed on both sides of the nasal septum for 30 seconds, collecting nasal secretions from the challenge site (ipsilateral) and the contralateral nostril. These disks were then immediately placed back into microtubes and weighed. The difference in their weight before and after challenge was the weight of produced nasal secretions, which was recorded in milligrams. Contralateral secretion weight for the diluent challenge was subtracted from that of the antigen challenge to compute this primary outcome measure.</description>
        <time_frame>10 minutes post diluent challenge and 10 minutes post antigen challenge</time_frame>
        <population>Excludes one patient who did not complete the second crossover intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Carbon Dioxide</title>
            <description>nasal Carbon dioxide, USP (CO2) administered 30 minutes prior to nasal challenge</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>nasal placebo administered 30 minutes prior to nasal challenge</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Diluent Challenge Contralateral Secretion Weight at Antigen Challenge</title>
          <description>Fifty microliters of challenge solutions were placed on the disks, which were then applied to the nasal septum for 1 minute. Thirty seconds after removal, two preweighed filter paper disks were placed on both sides of the nasal septum for 30 seconds, collecting nasal secretions from the challenge site (ipsilateral) and the contralateral nostril. These disks were then immediately placed back into microtubes and weighed. The difference in their weight before and after challenge was the weight of produced nasal secretions, which was recorded in milligrams. Contralateral secretion weight for the diluent challenge was subtracted from that of the antigen challenge to compute this primary outcome measure.</description>
          <population>Excludes one patient who did not complete the second crossover intervention.</population>
          <units>milligrams</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" lower_limit="-3.1" upper_limit="54.1"/>
                    <measurement group_id="O2" value="19.6" lower_limit="0" upper_limit="55.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Diluent Challenge Ipsilateral Secretion Weight at Antigen Challenge</title>
        <description>Fifty microliters of challenge solutions were placed on the disks, which were then applied to the nasal septum for 1 minute. Thirty seconds after removal, two preweighed filter paper disks were placed on both sides of the nasal septum for 30 seconds, collecting nasal secretions from the challenge site (ipsilateral) and the contralateral nostril. These disks were then immediately placed back into microtubes and weighed. The difference in their weight before and after challenge was the weight of produced nasal secretions, which was recorded in milligrams. Ipsilateral secretion weight for the diluent challenge was subtracted from that of the antigen challenge to compute this primary outcome measure.</description>
        <time_frame>10 minutes post diluent challenge and 10 minutes post antigen challenge</time_frame>
        <population>Excludes one patient who did not complete the second crossover intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Carbon Dioxide</title>
            <description>nasal Carbon dioxide, USP (CO2) administered 30 minutes prior to nasal challenge</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>nasal placebo administered 30 minutes prior to nasal challenge</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Diluent Challenge Ipsilateral Secretion Weight at Antigen Challenge</title>
          <description>Fifty microliters of challenge solutions were placed on the disks, which were then applied to the nasal septum for 1 minute. Thirty seconds after removal, two preweighed filter paper disks were placed on both sides of the nasal septum for 30 seconds, collecting nasal secretions from the challenge site (ipsilateral) and the contralateral nostril. These disks were then immediately placed back into microtubes and weighed. The difference in their weight before and after challenge was the weight of produced nasal secretions, which was recorded in milligrams. Ipsilateral secretion weight for the diluent challenge was subtracted from that of the antigen challenge to compute this primary outcome measure.</description>
          <population>Excludes one patient who did not complete the second crossover intervention.</population>
          <units>milligrams</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" lower_limit="-4.8" upper_limit="90.4"/>
                    <measurement group_id="O2" value="32.6" lower_limit="0" upper_limit="49.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Diluent Challenge Ipsilateral Histamine Level at Antigen Challenge</title>
        <description>After collection of nasal secretions after diluent or antigen challenge, the filter paper disks were replaced in Eppendorf tubes and the disk/tube combination was weighed to record produced secretions. Three hundred microleters of 0.9% sodium chloride solution was then placed in the tubes and mediators were allowed to elute from the disks for 24 hours at 4 degrees Celsius. The eluate was then transferred to tubes and stored at -20 degrees Celsius until assayed for histamine.
Histamine was assayed by ELISA (Oxford Biomedical Research, Oxford, MI). The lower limit of detection of the assay is 2.5 ng/mL and samples below the detection limit were arbitrarily assigned a value of 1.25 ng/mL. The ipsilateral measure was taken from the challenge site.
The number reported in this outcome measure was calculated by subtracting the ipsalateral histamine level at diluent challenge from the analogous measure recorded after antigen challenge. Values may be positive or negative.</description>
        <time_frame>10 minutes post diluent challenge and 10 minutes post antigen challenge</time_frame>
        <population>Excludes one patient who did not complete the second crossover intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Carbon Dioxide</title>
            <description>nasal Carbon dioxide, USP (CO2) administered 30 minutes prior to nasal challenge</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>nasal placebo administered 30 minutes prior to nasal challenge</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Diluent Challenge Ipsilateral Histamine Level at Antigen Challenge</title>
          <description>After collection of nasal secretions after diluent or antigen challenge, the filter paper disks were replaced in Eppendorf tubes and the disk/tube combination was weighed to record produced secretions. Three hundred microleters of 0.9% sodium chloride solution was then placed in the tubes and mediators were allowed to elute from the disks for 24 hours at 4 degrees Celsius. The eluate was then transferred to tubes and stored at -20 degrees Celsius until assayed for histamine.
Histamine was assayed by ELISA (Oxford Biomedical Research, Oxford, MI). The lower limit of detection of the assay is 2.5 ng/mL and samples below the detection limit were arbitrarily assigned a value of 1.25 ng/mL. The ipsilateral measure was taken from the challenge site.
The number reported in this outcome measure was calculated by subtracting the ipsalateral histamine level at diluent challenge from the analogous measure recorded after antigen challenge. Values may be positive or negative.</description>
          <population>Excludes one patient who did not complete the second crossover intervention.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-2.7" upper_limit="16.6"/>
                    <measurement group_id="O2" value="2.04" lower_limit="0" upper_limit="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Diluent Challenge Contralateral Histamine Level at Antigen Challenge</title>
        <description>After collection of nasal secretions after diluent or antigen challenge, the filter paper disks were replaced in Eppendorf tubes and the disk/tube combination was weighed to record produced secretions. Three hundred microleters of 0.9% sodium chloride solution was then placed in the tubes and mediators were allowed to elute from the disks for 24 hours at 4 degrees Celsius. The eluate was then transferred to tubes and stored at -20 degrees Celsius until assayed for histamine.
Histamine was assayed by ELISA (Oxford Biomedical Research, Oxford, MI). The lower limit of detection of the assay is 2.5 ng/mL and samples below the detection limit were arbitrarily assigned a value of 1.25 ng/mL. The ipsilateral measure was taken from the challenge site.
The number reported in this outcome measure was calculated by subtracting the contralateral histamine level at diluent challenge from the analogous measure recorded after antigen challenge. Values may be positive or negative.</description>
        <time_frame>10 minutes post diluent challenge and 10 minutes post antigen challenge</time_frame>
        <population>Excludes one patient who did not complete the second crossover intervention.</population>
        <group_list>
          <group group_id="O1">
            <title>Carbon Dioxide</title>
            <description>nasal Carbon dioxide, USP (CO2) administered 30 minutes prior to nasal challenge</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>nasal placebo administered 30 minutes prior to nasal challenge</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Diluent Challenge Contralateral Histamine Level at Antigen Challenge</title>
          <description>After collection of nasal secretions after diluent or antigen challenge, the filter paper disks were replaced in Eppendorf tubes and the disk/tube combination was weighed to record produced secretions. Three hundred microleters of 0.9% sodium chloride solution was then placed in the tubes and mediators were allowed to elute from the disks for 24 hours at 4 degrees Celsius. The eluate was then transferred to tubes and stored at -20 degrees Celsius until assayed for histamine.
Histamine was assayed by ELISA (Oxford Biomedical Research, Oxford, MI). The lower limit of detection of the assay is 2.5 ng/mL and samples below the detection limit were arbitrarily assigned a value of 1.25 ng/mL. The ipsilateral measure was taken from the challenge site.
The number reported in this outcome measure was calculated by subtracting the contralateral histamine level at diluent challenge from the analogous measure recorded after antigen challenge. Values may be positive or negative.</description>
          <population>Excludes one patient who did not complete the second crossover intervention.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-1.2" upper_limit="1.7"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Eosinophil Influx [Pre-allergen]</title>
        <description>The number of eosinophils per 200 white blood cells was counted for each nasal secretion scraping. The percentage of eosinophils was recorded.</description>
        <time_frame>before antigen challenge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Carbon Dioxide</title>
            <description>nasal Carbon dioxide, USP (CO2) administered 30 minutes prior to nasal challenge</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>nasal placebo administered 30 minutes prior to nasal challenge</description>
          </group>
        </group_list>
        <measure>
          <title>Eosinophil Influx [Pre-allergen]</title>
          <description>The number of eosinophils per 200 white blood cells was counted for each nasal secretion scraping. The percentage of eosinophils was recorded.</description>
          <units>percentage of white blood cells</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Eosinophil Influx [Post-allergen]</title>
        <description>The number of eosinophils per 200 white blood cells was counted for each nasal secretion scraping. The percentage of eosinophils was recorded.</description>
        <time_frame>after antigen challenge</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Carbon Dioxide</title>
            <description>nasal Carbon dioxide, USP (CO2) administered 30 minutes prior to nasal challenge</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>nasal placebo administered 30 minutes prior to nasal challenge</description>
          </group>
        </group_list>
        <measure>
          <title>Eosinophil Influx [Post-allergen]</title>
          <description>The number of eosinophils per 200 white blood cells was counted for each nasal secretion scraping. The percentage of eosinophils was recorded.</description>
          <units>percentage of white blood cells</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="31"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Carbon Dioxide</title>
          <description>nasal Carbon dioxide, USP (CO2) administered 30 minutes prior to nasal challenge</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>nasal placebo administered 30 minutes prior to nasal challenge</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="13"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert M. Naclerio, MD</name_or_title>
      <organization>The University of Chicago</organization>
      <phone>(773) 702-1865</phone>
      <email>rnacleri@surgery.bsd.uchicago.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

